News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neuropharm Group plc - US Appointment



1/20/2009 11:49:40 AM

Surrey--(Marketwire - January 19, 2009) - For immediate release 19 January 2009

Neuropharm Group Plc

("Neuropharm" or "the Company")

US Brand Leader Appointed for NPL-2008

Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on the development of medicines for the treatment of neurodevelopmental disorders, is pleased to announce the appointment of Chris Mario to the position of Brand Leader within the Company's US operating unit, Neuropharm Inc, in Radnor, Pennsylvania.

She has a strong track record in strategic planning and marketing, and more than 20 years' experience in pharmaceutical marketing and sales. Most recently she served as Executive Director of US and Global Marketing within Wyeth Pharmaceuticals' biopharma business unit. Prior to joining Wyeth, Chris held the position of Head of US Marketing for Dermik Laboratories, a Sanofi-Aventis company. Chris brings a wealth of in-line brand management and launch planning expertise from across a variety of specialty product categories, including products with Orphan Drug Designation and a paediatric focus.

Chris's appointment marks a further step in the formation of Neuropharm's specialised marketing and sales team in the US in preparation for the commercial launch of NPL-2008, the Company's novel autism treatment. Phase III results from the Company's SOFIA trial of NPL-2008 are expected in Q1 2009 and the product is on track for the completion of its regulatory submission to FDA in Q2 2009.

Commenting on this appointment, Bob Prachar, Neuropharm Inc President US Operations, said: "We are delighted that Chris has joined our team in the US. She has deep experience in marketing and new product introductions and a strong appreciation for the unique needs of paediatric patients. Chris will be involved in all aspects of our US business and will lead the launch readiness planning for NPL-2008, which will be pivotal to our overall commercial success."

For further information please contact:

Neuropharm

+ 44 (0) 1372 371 171

Robert Mansfield, Chief Executive Officer

Piper Jaffray Ltd.

+ 44 (0) 20 3142 8700

Neil Mackison, Rupert Winckler

For UK and European media and investor enquiries:

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court, Mary-Jane Johnson, Catherine Breen

For US media and investor enquiries:

Weber Shandwick

+1 212 445 8113

Traci Mogil

Notes to Editors:

About Neuropharm

Neuropharm is a specialty pharmaceutical company focused on improving patient lives by delivering medicines for high unmet needs in the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES